Advertisement
Advertisement
XFOR
X4 Pharmaceuticals, Inc. Common Stock
3.85
USDSponsored
-0.15
-3.77%
Feb 04, 16:00 UTC -5
Closed
After-Market
3.86
+0.01
+0.29%
XFOR Earnings Reports
Positive Surprise Ratio
XFOR beat 17 of 31 last estimates.
55%
Next Report
Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.77M
/-$0.38
Implied change from Q3 25 (Revenue/ EPS)
+0.15%
/-44.93%
Implied change from Q4 24 (Revenue/ EPS)
+23.27%
/-93.67%
X4 Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 05, 2025, XFOR reported earnings of -0.69 USD per share (EPS) for Q3 25, beating the estimate of -0.93 USD, resulting in a 26.15% surprise. Revenue reached 1.76 million, compared to an expected 2.08 million, with a -15.25% difference. The market reacted with a -10.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 1.77 million USD, implying an decrease of -44.93% EPS, and increase of 0.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were X4 Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, X4 Pharmaceuticals, Inc. Common Stock reported EPS of -$0.69, beating estimates by 26.15%, and revenue of $1.76M, -15.25% below expectations.
How did the market react to X4 Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -10.58%, changed from $3.97 before the earnings release to $3.55 the day after.
When is X4 Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for X4 Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 6
analysts, X4 Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $1.77M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement